Jacobs Levy Equity Management Inc. Makes New $887,000 Investment in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Jacobs Levy Equity Management Inc. bought a new position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,385,301 shares of the company's stock, valued at approximately $887,000. Jacobs Levy Equity Management Inc. owned 0.47% of Lyell Immunopharma at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Decheng Capital LLC acquired a new stake in Lyell Immunopharma during the fourth quarter worth approximately $7,622,000. Foresite Capital Management V LLC acquired a new stake in Lyell Immunopharma during the fourth quarter worth approximately $5,205,000. Geode Capital Management LLC grew its stake in Lyell Immunopharma by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company's stock worth $2,648,000 after purchasing an additional 117,303 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Lyell Immunopharma by 43.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,645,787 shares of the company's stock worth $1,053,000 after purchasing an additional 498,417 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Lyell Immunopharma by 716.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company's stock worth $1,032,000 after purchasing an additional 1,414,746 shares during the period. Institutional investors and hedge funds own 66.05% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "neutral" rating and issued a $1.00 price target on shares of Lyell Immunopharma in a report on Wednesday, April 16th.

Insider Activity

In related news, CEO Lynn Seely bought 175,000 shares of the company's stock in a transaction dated Friday, March 14th. The shares were bought at an average price of $0.61 per share, for a total transaction of $106,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 712,500 shares of the company's stock, valued at $434,625. This trade represents a 32.56% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Charles W. Newton bought 200,000 shares of the company's stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $0.56 per share, for a total transaction of $112,000.00. Following the acquisition, the chief financial officer now directly owns 200,000 shares of the company's stock, valued at approximately $112,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 768,640 shares of company stock worth $449,508 over the last 90 days. 25.10% of the stock is currently owned by corporate insiders.

Lyell Immunopharma Stock Up 5.4%

NASDAQ:LYEL traded up $0.02 on Thursday, hitting $0.43. The stock had a trading volume of 207,475 shares, compared to its average volume of 1,033,320. The business's fifty day moving average is $0.46 and its 200 day moving average is $0.65. The company has a market cap of $127.59 million, a PE ratio of -0.55 and a beta of -0.25. Lyell Immunopharma, Inc. has a 52 week low of $0.39 and a 52 week high of $2.85.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. The business had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. Equities analysts predict that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.